Goldman Sachs Group Inc Cure Vac N.V. Transaction History

Goldman Sachs Group Inc

  • $613 Billion
  • Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Cure Vac N.V. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 343,345 shares of CVAC stock, worth $1.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
343,345
Previous 372,918 7.93%
Holding current value
$1.13 Million
Previous $1.1 Million 6.75%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
SELL
$2.49 - $3.41 $73,636 - $100,843
-29,573 Reduced 7.93%
343,345 $1.17 Million
Q3 2024

Nov 14, 2024
SELL
$2.74 - $3.79 $60,781 - $84,073
-22,183 Reduced 5.61%
372,918 $1.1 Million
Q2 2024

Aug 13, 2024
BUY
$2.31 - $4.99 $164,624 - $355,617
71,266 Added 22.01%
395,101 $1.34 Million
Q1 2024

May 15, 2024
SELL
$2.94 - $4.34 $135,107 - $199,444
-45,955 Reduced 12.43%
323,835 $981,000
Q4 2023

Feb 13, 2024
SELL
$3.96 - $6.41 $578,999 - $937,218
-146,212 Reduced 28.34%
369,790 $1.56 Million
Q3 2023

May 14, 2024
BUY
$6.5 - $10.77 $950,378 - $1.57 Million
146,212 Added 39.54%
516,002 $3.52 Million
Q3 2023

Nov 14, 2023
BUY
$6.5 - $10.77 $326,378 - $540,783
50,212 Added 10.78%
516,002 $3.52 Million
Q2 2023

May 14, 2024
BUY
$6.69 - $12.25 $7,686 - $14,075
1,149 Added 0.25%
465,790 $4.85 Million
Q2 2023

Aug 14, 2023
BUY
$6.69 - $12.25 $7,686 - $14,075
1,149 Added 0.25%
465,790 $4.85 Million
Q1 2023

May 14, 2024
BUY
$6.38 - $12.5 $1.59 Million - $3.11 Million
248,870 Added 115.34%
464,641 $3.24 Million
Q1 2023

May 11, 2023
BUY
$6.38 - $12.5 $1.59 Million - $3.11 Million
248,870 Added 115.34%
464,641 $3.24 Million
Q4 2022

May 14, 2024
SELL
$5.75 - $8.5 $984,428 - $1.46 Million
-171,205 Reduced 44.24%
215,771 $1.3 Million
Q4 2022

Feb 13, 2023
SELL
$5.75 - $8.5 $984,428 - $1.46 Million
-171,205 Reduced 44.24%
215,771 $1.3 Million
Q3 2022

May 14, 2024
SELL
$7.48 - $15.24 $2.08 Million - $4.24 Million
-278,294 Reduced 41.83%
386,976 $3.05 Million
Q3 2022

Nov 10, 2022
SELL
$7.48 - $15.24 $2.08 Million - $4.24 Million
-278,294 Reduced 41.83%
386,976 $3.05 Million
Q2 2022

May 14, 2024
BUY
$13.18 - $19.41 $3.89 Million - $5.74 Million
295,480 Added 79.9%
665,270 $9.05 Million
Q2 2022

Aug 15, 2022
BUY
$13.18 - $19.41 $5.06 Million - $7.45 Million
384,046 Added 136.56%
665,270 $9.05 Million
Q1 2022

May 16, 2022
SELL
$14.73 - $35.25 $906,381 - $2.17 Million
-61,533 Reduced 17.95%
281,224 $5.52 Million
Q4 2021

Feb 14, 2022
BUY
$33.72 - $48.22 $7.6 Million - $10.9 Million
225,397 Added 192.06%
342,757 $11.8 Million
Q3 2021

Nov 10, 2021
BUY
$49.26 - $74.5 $5.78 Million - $8.74 Million
117,360 New
117,360 $6.41 Million

Others Institutions Holding CVAC

# of Institutions
86
Shares Held
10.5M
Call Options Held
75.5K
Put Options Held
33.5K
View Full List

About CureVac N.V.

CVAC Quotes by TradingView
  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $619M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email